Chimeric antigen receptors for T-cell malignancies

Lauren D. Scherer, Malcolm Brenner, Maksim Mamonkin

Research output: Contribution to journalReview articlepeer-review

47 Scopus citations


Development of chimeric antigen receptor (CAR)-modified T cells for the treatment of T-lineage leukemia and lymphoma has encountered several unique challenges. The most widely expressed tumor antigen targets for malignant T cells are often also expressed on non-malignant T cells. Transducing T cells with CARs targeted to these shared antigens can therefore promote over-activation or fratricide of CAR T cells, reducing their therapeutic potency. If fratricide is resolved, clinical CAR T cell activity may eliminate normal T-cell subsets and cause temporary immunosuppression. In this review, we summarize the preclinical development of CAR-based therapies for T-cell malignancies and discuss strategies to minimize toxicities associated with on-target fratricide and off-tumor activity.

Original languageEnglish (US)
Article number126
JournalFrontiers in Oncology
Issue numberMAR
StatePublished - 2019


  • Chimeric antigen receptors (CARs)
  • Immunotherapy
  • Non-Hodgkin lymphoma
  • T cell malignancy
  • T-cells

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Chimeric antigen receptors for T-cell malignancies'. Together they form a unique fingerprint.

Cite this